Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease

Citation
M. Cazzola et al., Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease, EUR J CL PH, 54(11), 1999, pp. 829-833
Citations number
23
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
ISSN journal
00316970 → ACNP
Volume
54
Issue
11
Year of publication
1999
Pages
829 - 833
Database
ISI
SICI code
0031-6970(199901)54:11<829:OBCTIS>2.0.ZU;2-Y
Abstract
Objective: There is now good evidence that inhaled salmeterol is an effecti ve agent in chronic obstructive pulmonary disease (COPD), but, at the prese nt time, data on the effects of bambuterol, which is an oral tarbutaline pr o-drug, in patients with COPD are scarce. Moreover, no comparative study be tween bambuterol and salmeterol in patients with chronic obstructive airway disorders has been published. The objective of this research was, conseque ntly, to compare the efficacy and safety of 20 mg oral bambuterol and 50 mu g inhaled salmeterol in patients with partially reversible COPD. Methods: The speed and length of bronchodilation with 20 mg bambuterol and 50 mu g inhaled salmeterol were compared in 16 patients with partially reve rsible COPD. The investigation and designed as a double-blind, double-dummy , cross-over, placebo controlled and randomised study. Lung function (FEV1, FVC) and systemic variables (subjective tremor, heart rate, blood pressure ) were monitored prior to the administration of the drug and for 12 h after each agent on 3 non-consecutive days. Results: Inhalation of salmeterol induced a significant (P < 0.05) increase of lung function when compared with placebo. In addition, oral bambuterol elicited good bronchodilation, with its maximum slightly later than for sal meterol. The mean (+/-SE) AUC(0-12) S-h for all patients were 3.1341 +/- 0. 553 for salmeterol and 1963 1 +/- 0.573 for bambuterol. Both AUC(0-12 h) s were significantly greater than for placebo (P < 0.05), but there was no si gnificant difference (P = 0.077) between the Salmeterol and bambuterol AUC( 0-12 h) s Bambuterol, but not saImeterol, caused tremor in four patients. M oreover, it induced a higher heart rate when compared with salmeterol at ea ch considered time after the administration of the drug; differences after 9 and 12 h were statistically significant (P < 0.05). Conclusion: Both oral bambuterol and inhaled salmeterol resulted in good br onchodilation in patients with stable COPD. However, bambuterol, but not sa lmeterol, caused tremor in several subjects and elicited a more pronounced tachycardia.